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doi:10.1016/j.jtcvs.2005.10.026bjective: Sternal wound complications are devastating events occurring in coro-
ary artery bypass surgery, particularly in patients with diabetes. Prostaglandin E2
eceptors have 4 subtypes, and the activation of the EP4 receptor induces bone
egeneration. The present study investigated the utility of a prostaglandin E2 EP4
eceptor–selective agonist in sternal healing after median sternotomy with the removal
f the bilateral internal thoracic arteries in diabetic rats.
ethods: Diabetic Wistar rats with blood glucose levels of greater than 400 mg/dL
ere established by means of a single intraperitoneal injection of streptozotocin.
fter median sternotomy and bilateral internal thoracic artery removal in 16 diabetic
ats, 8 rats were administered the EP4 agonist (300 g) on the posterior table of the
ternum (EP4 group), whereas 8 did not receive any treatment (control group).
ternal healing and incidence of sternal wound complications were evaluated 4
eeks after the operation.
esults: Sternal wound complications developed in 5 rats in the control group but
n only 1 rat in the EP4 group (P  .01). Histologic examination revealed an almost
ompletely healed sternum filled with regenerated bone tissue only in the EP4
roup. Both bone mineral content and bone mineral density, as assessed with
ual-energy x-ray absorptiometry, were higher in the EP4 group than in the control
roup (71.7  12.1 vs 48.9  11.7 mg for bone mineral content [P  .01] and
6.8  14.6 vs 47.9  6.3 mg/mm2 for bone mineral density [P  .05]).
onclusions: The prostaglandin E2 EP4 agonist accelerated the sternal healing and
ecreased the incidence of sternal wound complications in the diabetic ischemic
ternum. This method might help in decreasing sternal necrosis in high-risk patients
r permit wider application of bilateral internal thoracic arteries in coronary artery
ypass surgery, even in patients with diabetes.
ternal wound complications (SWCs; ie, sternal dehiscence [instability], in-
fection after median sternotomy, or both) are potentially devastating events
occurring after cardiac surgery.1,2 Bilateral internal thoracic artery (BITA)
rafting after median sternotomy in coronary artery bypass surgery carries a high
isk of SWCs, particularly in patients with diabetes mellitus.3-6 Therefore, the use of
ITA grafts in patients with severe diabetes remains controversial, although some
nstitutions have little concern regarding SWCs.7,8
Sternal ischemia is an important risk factor for SWCs. In addition, delayed sternal
ealing followed by sternal dehiscence is another important risk factor for SWCs.1-6
herefore both sternal blood perfusion recovery (angiogenesis) and the acceleration of
ternal healing (osteogenesis) might be important for the prevention of SWCs.
We have previously reported that topical use of a gelatin hydrogel sheet incor-
orated with basic fibroblast growth factor (bFGF), a potent angiogenic and osteo-
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CDenic factor, ameliorated sternal ischemia and prevented
WCs.9,10 However, in these series bFGF alone could not
ompletely prevent SWCs, and this might be attributed to
he insufficient osteogenic effects of bFGF compared with
ts strong angiogenic effects.
Prostaglandins (PGs) are a group of lipid mediators pro-
uced from arachidonic acid and are found in various tis-
ues.11,12 PGE2 stimulates bone formation and increase the
one mass in vivo. Four types of PGE2 receptors (ie, EP1,
P2, EP3, and EP4) have been identified, and EP4 is the
ajor receptor that mediates bone formation.11-15
We have developed a PGE2 EP4 receptor–selective ag-
nist that induces bone regeneration.15 In the present study
e tested the hypothesis that the EP4 receptor–selective
gonist accelerates sternal healing and decreases the inci-
ence of SWCs after median sternotomy with BITA re-
oval in streptozotocin-induced diabetic rats.
aterials and Methods
hemicals
n EP4 receptor–selective agonist, ONO-4819 (methyl 7-[(1R, 2R,
R)-3-hydroxy-2-[(E)-(3S)-3-hydroxy-4-(m-methoxymethylphenyl)-
-butenyl]-5-oxocyclopentyl]-5-thiaheptanoate; Patent Cooperation
reaty publication no. WO 00/03980), shows inhibition constant
alues of 0.7, 56, and 620 nmol/L for radioligand binding to EP4,
P3, and EP2, respectively, and values of more than 10 mol/L for
P1 and receptors for PGD2, PGF2, PGI2, or thromboxane A2.15
reparation of Copoly Lactic Acid/Glycolic Acid
icrospheres Containing the PGE2 EP4 Agonist
o have effective bone-forming activities, ONO-4819 needs re-
eated injection because of its short half-life.15 We used copoly
actic acid/glycolic acid (PLGA) as a slow-release carrier for the
gonist. To obtain desirable release profile of the agonist from the
LGA, ONO-AE2-724 was produced as a prodrug of ONO-4819
y introducing an acyl chain (C9) to its carboxylic part.
ONO-AE2-724 (10 mg) and PLGA75-65 (90 mg) were dis-
olved in 1 mL of dichloromethane as the oil phase. The oil phase
as gradually added into aqueous polyvinylalcohol (0.1%) solu-
ion under stirring with a turbine-shaped mixer (Homomixer) at
000 rpm to obtain oil-in-water emulsion. Then the PLGA micro-
pheres were suspended in the polyvinylalcohol solution after
Abbreviations and Acronyms
bFGF  basic fibroblast growth factor
BITA  bilateral internal thoracic artery
BMC  bone mineral content
BMD  bone mineral density
DEXA dual-energy x-ray absorptiometry
PG  prostaglandin
PLGA copoly lactic acid/glycolic acid
SWC  sternal wound complicationrganic solvent evaporation. Supernatant was discarded and re- l
88 The Journal of Thoracic and Cardiovascular Surgery ● Marclaced with fresh water or aqueous medium containing 0.2%
ween 80. Washed microsphere precipitation was lyophilized to
emove residual organic solvent and water, and then dried solid
NO-AE2-724 microspheres were recovered. ONO-AE2-724 was
lowly released from the PLGA microspheres approximately for 4
eeks.
reparation of Fibrin Glue as a Scaffold of the PLGA
icrospheres Containing the EP4 Agonist
e used fibrin glue as a scaffold of the PLGA microspheres
ontaining the EP4 agonist. Tisseel (1.0-mL kit, Baxter) was
repared according to the manufacturer’s instructions. Briefly, the
ontents of the thrombin vial were resuspended with 0.5 mL of
aCl2 solution, and the sealer proteins in the second vial were recon-
tituted with 0.5 mL of aprotinin solution. Both vials were warmed at
7°C for 5 minutes, with constant stirring to ensure complete disso-
ution. The PLGA microspheres incorporating the EP4 agonist were
ispersed to the thrombin solution. When the operation was near
ompletion, the contents of each vial were drawn into separate
yringes and attached to the applicator device, and 200 L of fibrin
lue was delivered to the posterior table of the sternum.
nimals
Preparation of rats with sternal ischemia after median ster-
otomy. Rats with sternal ischemia after median sternotomy were
repared as previously described.9,10 In brief, median sternotomy
as performed by using a rotating saw, and the BITAs were
igated with 6-0 polypropylene sutures near the origin and at the
istal bifurcation. Then the BITAs, with their beds, were destroyed
y use of an electrical coagulator.
Induction of diabetes mellitus. Male Wistar rats weighing
etween 250 and 300 g were used for diabetic models. Diabetic
ats were created by means of a single intraperitoneal injection of
5 mg/kg streptozotocin (Wako Chemicals) in 0.1 mol/L citrate
uffer (pH 4.9). Diabetes mellitus was defined by both an increase
n blood glucose levels of greater than 400 mg/dL and a loss of
ody weight of greater than 15 g 2 weeks after the injection.
The Kyoto University Animal Experiment Committee ap-
roved the experiments. Animals were cared for in compliance
ith the “Guide for the care and use of laboratory animals,”
nstitute of Laboratory Animal Resources, Commission on Life
ciences, National Research Council.
tudy Group Profiles
Study 1: Dose effects of the EP4 agonist in sternal healing
fter median sternotomy. To determine the therapeutic dose of
he EP4 agonist, we evaluated the dose effects of the EP4 agonist
n nondiabetic-nonischemic sternum. Thirty-six nondiabetic rats
ith median sternotomies were randomly divided into 6 groups
Figure 1): rats in the EP4-treated groups had fibrin glue contain-
ng the PLGA microsphere with various doses of the EP4 agonist
1000, 300, and 100 g, respectively) on the posterior table of the
ternum; rats in the control group had no treatment; and rats in the
ehicle group had fibrin glue containing the PLGA microspheres
ithout the EP4 agonist on the posterior table of the sternum. In
ddition, unmanipulated rats were also evaluated.
Rats were killed by means of intravenous administration of aethal dose of sodium pentobarbital 4 weeks after the operation.
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CDhe sternum was excised and fixed in 10 wt% formaldehyde
olution in phosphate-buffered saline for 4 days to assess the
xtent of the sternal healing.
Study 2: Effects of the EP4 agonist on diabetic rats with
edian sternotomies with the BITAs removed. The 16 diabetic
ats that had median sternotomies and BITA removal were ran-
omly divided into 2 groups (n  8 each): rats in the EP4 group
ad fibrin glue containing the PLGA microspheres incorporated
ith a therapeutic dose of the EP4 agonist on the posterior table of
he sternum before closing the sternum, whereas rats in the control
roup had the fibrin glue containing the PLGA microspheres
ithout the EP4 agonist in the same manner. The sample of the
ternum was harvested as described in study 1 for histologic
ssessment.
ssessment of Sternal Bone Healing
Dual-energy x-ray absorptiometry. Qualitative and quantita-
ive analysis of bone regeneration was assessed on the basis of
one mineral content (BMC) and bone mineral density (BMD).
he BMC and BMD of each sternum were measured with dual-
nergy x-ray absorptiometry (DEXA) by using a bone mineral
nalyzer (Dichroma Scan 600, Aloka Co) 4 weeks after the oper-
tion. The instrument was calibrated with a phantom of known
ineral content. Each scan was performed at a speed of 20 mm/s,
nd the scanning length was 1 mm.
Soft x-ray film analysis. Soft (high-contrast) x-ray films of the
ternum were taken at 46 kV and 2 mA for 45 seconds by use of
n x-ray apparatus (type CMB, Koizumi X-Senkosha). Films of
ormalin-fixed bone specimens from different experimental groups
igure 1. Dose effects of the EP4 agonist assessed by means of
ual-energy x-ray absorptiometry. Dose effects of the EP4 agonist
ere evaluated in nondiabetic-nonischemic murine sternum after
edian sternotomy. Bone mineral content (BMC) and bone min-
ral density (BMD) were measured 4 weeks after the operation:
-c, the EP4-treated groups (rats treated with 1000 g [a], 300 g
b], and 100 g [c] of the EP4 agonist); d, the control group (rats
ithout treatment); e, the vehicle group (rats with vehicle alone);
nd f, the unmanipulated group. *P < .01 and #P < .05 vs control;
P < .05 vs 100 g of the EP4 agonist. n.s., Not significant.ere taken with the use of the same type of x-ray film. t
The Journal of ThoracicHistology. Bone specimens were demineralized in 10 wt%
thylenediamine tetraacetic acid solution at 4°C for 3 days, em-
edded in paraffin, and sectioned at 10-m thickness. The sections
ere obtained at the third, fourth, and fifth intercostal spaces of the
ternum and stained with hematoxylin and eosin 4 weeks after the
peration. The histologic sections were analyzed by use of a
icroscope equipped with a video camera connected to an image
nalysis system (SP-1000, Olympus).
ssessment of Peristernal Blood Perfusion Recovery
Measurement of peristernal blood perfusion. Peristernal
lood perfusion was measured with a laser Doppler perfusion
mage analyzer (Moor Instruments) before the median sternotomy,
fter closure of the sternum, and 4 weeks after the operation, as
reviously described.16,17 Excess hairs were removed with surgi-
al clippers the day before scanning. Rats were placed on a heating
late at 37°C to minimize temperature variation. The Laser Dopp-
er imaging measured the blood perfusion in the 4-cm length 
.5-cm width of bilateral peristernal areas. The average blood flow
as calculated for evaluation.
Histology. The peristernal number of vessels was counted, as
reviously described.9 Briefly, arterioles (25 and 100 m in
xternal diameter) and capillaries (25 m in external diameter)
ere counted in preparations stained with hematoxylin and eosin
n a 200 field (0.442 mm2 per unit area). Five fields were chosen
andomly from the connective tissue around the sternum. Two
athologists blinded to treatment counted the number of vessels
er unit area.
tatistical Analysis
xperimental results are expressed as means standard deviation.
ultiple group comparisons were performed by using analysis of
ariance. In multiple comparisons among independent groups in
hich analysis of variance indicated significant differences, the
tatistical value was determined according to the Bonferroni-Dunn
ethod. Statistical analysis comparing 2 groups was performed
ith the Wilcoxon rank sum test for means or the Fisher exact
robability test for categoric variables. All statistical analyses were
erformed with Statview software (Abacus).
esults
tudy 1: Dose Effects of the EP4 Agonist
either the BMC nor the BMD in the vehicle group differed
rom those in the control group at 4 weeks after the opera-
ion (Figure 1). In contrast, all 3 doses of the EP4 agonist
roduced a significant increase in both the BMC and BMD.
he BMC and BMD of rats treated with 300 g of the EP4
gonist were significantly higher than those of rats treated
ith 100 g (93.6  13.8 vs 71.4  11.7 mg for BMC and
1.1  11.9 vs 73.1  7.3 mg/mm2 for BMD; P  .05,
espectively; Figure 1). However, the effects of 300 g and
000 g of the EP4 agonist were not significantly different
rom each other (93.6  13.8 vs 98.3  10.5 mg for BMC
nd 91.1 11.9 vs 95.3 12.3 mg/mm2 for BMD, Figure 1).
herefore 300 g of the EP4 agonist was used as theherapeutic dose in study 2.
and Cardiovascular Surgery ● Volume 131, Number 3 589
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CDtudy 2: Prevention of SWCs by the EP4 Agonist
Assessment of sternal bone regeneration
INCIDENCE OF SWCS. SWCs were diagnosed by using a
oft x-ray film of the sternum (Figure 2, A). Destruction or
ehiscence of the separated original sternum was clearly
bserved in the rats with SWCs. Four weeks after the
peration, SWCs developed in 5 rats in the control group
igure 2. Soft x-ray films and the incidence of sternal wound
omplications (SWCs) 4 weeks after the operation. A, Soft x-ray
lms of SWCs. Sternal dehiscence or destruction caused by SWCs
as clearly observed. B, Incidence of SWCs. Numbers of diabetic
ats with SWCs (filled bar) were shown (n  8 for each group).
he open bar shows rats without SWCs. The incidence of SWCs
as significantly lower in the EP4 group. *P < .01 vs control.
Figure 3. Effects of the EP4 agonist on sternal regenera
show sternal regeneration 4 weeks after the operati
treatment (control). Sternal dehiscence was observed
dehiscence clearly disappeared in the EP4 group.
90 The Journal of Thoracic and Cardiovascular Surgery ● Marcut in only 1 rat in the EP4 group (63% and 13%, P  .01;
igure 2, B). All the rats with SWCs had macroscopic
bscesses in the anterior mediastinum.
STERNAL HEALING AFTER STERNOTOMY. Regarding the ster-
al healing without the SWCs in each group, dehiscence of
he separated original sternum was observed in the control
roup (Figure 3, B). In contrast, sternal union and almost
omplete bone healing was observed in the EP4 group
Figure 3, A), and thus almost complete bone healing was
bserved only in the EP4 group.
DUAL-ENERGY X-RAY ABSORPTIOMETRY. As illustrated in
ig 4, A, the BMC of the regenerated sternum assessed on
he basis of DEXA was higher in the EP4 group than in the
ontrol group (71.7  12.1 vs 48.9  11.7 mg, P  .01).
he BMD of the regenerated sternum was also higher in the
P4 group than in the control group (66.8 14.6 vs 47.9
.3 mg/mm2, P  .05).
HISTOLOGIC ANALYSIS. Figure 5 shows histologic sections
f the sternum 4 weeks after the operation. The rats in the EP4
roup showed almost completely healed sternums filled with
egenerated bone tissue and bone marrow (Figure 5, A), except
rat that showed poor sternal healing because of SWCs.
onversely, slight bone regeneration between the incised orig-
nal sternum was observed in the control group (Figure 5, B).
Assessment of peristernal blood perfusion
LASER DOPPLER PERFUSION ANALYZER. Figure 6, A, shows
he peristernal blood perfusion immediately after the re-
oval of the BITAs and 4 weeks after the operation in each
roup. The blood perfusion immediately after BITA re-
oval previously showed a similar decrease in both groups
as shown by means of soft x-ray films. Soft x-ray films
, Sternum was treated with the EP4 agonist. B, No
in the control group (white arrows), whereas sternaltion
on. A
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CD50.6%  8.3% and 51.3%  6.5% of the preoperative
evel, respectively). Four weeks after the operation, there was
o significant difference observed in the peristernal blood
erfusion between groups (77.8%  9.1% vs 73.9% 
0.3%). However, the blood perfusion had naturally recov-
red in both groups when compared with that immediately
fter BITA removal.
HISTOLOGIC ANALYSIS. Figure 6, B, shows the number of
rterioles and capillaries per unit area around the sternum 4
eeks after the operation in both groups. No difference was
bserved in the number of vessels between the groups
17.2  3.8 vs 15.5  4.5 vessels per unit area).
iscussion
he present study demonstrates the utility of the PGE2 EP4
eceptor–selective agonist for the acceleration of sternal
igure 4. Quantitative and qualitative analysis of sternal bone
egeneration assessed by means of dual-energy x-ray absorpti-
metry. Bone mineral content (BMC; A) and bone mineral density
BMD; B) 4 weeks after the operation are shown. Both the BMC
nd BMD significantly increased only in the EP4 group. *P < .01
nd #P < .05 vs control.
Figure 5. Histologic cross-sections of hematoxylin an
operation. A, Regenerated sternum with new bone was o
bone was observed partially in the control group. NB, New b
The Journal of Thoracicealing and reduction in the incidence of SWCs after me-
ian sternotomy with the removal of BITAs in diabetic rats.
oft x-ray film showed complete sternal healing only in the
ats treated with the EP4 agonist. The agonist significantly
ncreased both the BMC and BMD of the sternum, although
t did not increase the peristernal blood perfusion. An im-
ortant observation was that the EP4 agonist decreased the
ncidence of SWCs. This therapeutic approach would po-
entially not only facilitate the wider application of BITAs
n coronary artery bypass surgery, particularly in high-risk
iabetic patients, but also enable fast-track recovery.
Slow release of the PGE2 EP4 receptor–selective agonist
rom the PLGA microspheres might be a more effective and
ess invasive strategy for bone regeneration than the sys-
in–stained sternum were obtained 4 weeks after the
ved in the EP4 group. B, Regenerated sternum with new
igure 6. Evaluation of peristernal blood perfusion recovery.
, Laser Doppler perfusion image analyzer measurements imme-
iately after removal of BITA and 4 weeks after the operation are
hown. The EP4 agonist did not recover the blood perfusion in the
eristernum in both groups. B, The EP4 agonist did not increase
he peristernal number of vessels in both groups. BITA, Bilateral
nternal thoracic artery.d eos
bserone with bone marrow. (Original magnification 1.)
and Cardiovascular Surgery ● Volume 131, Number 3 591
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CDemic administration of PGE2. A noteworthy finding is that
he new bone induced by PGE2 was mainly composed of
brous tissues, whereas the trabeculae of the new bone
nduced by the EP4 agonist were well connected and suffi-
iently calcified and yielded substantial strength to the new
one.15 In addition, the systemic use of PGE2 is limited by
ndesirable effects, such as hypotension, diarrhea, contrac-
ion of the uterus, or thickening of the intestinal epithelium.
ecause the EP4 agonist acts selectively on one subtype of
he EP4 receptors, its use is expected to reduce several
dverse actions that are caused because of the systemic
dministration of PGE2. Furthermore, its slow-release sys-
em from the PLGA would enable dose reduction of the
gonist and might additionally contribute in the avoidance
f side effects. We expect the topical and sustained use of
he EP4 agonist to result in satisfactory bone regeneration
ithout systemic complications in human subjects.
Previously we have reported the utility of bFGF for the
revention of SWCs after median sternotomy with BITA
emoval in rats.9,10 However, the EP4 agonist might be
ore effective in bone regeneration than bFGF. Callus
emodeling is accelerated by bFGF by means of both os-
eoblastic callus formation and osteoclastic callus resorp-
ion, thereby resulting in bone regeneration.18,19 On the
ther hand, the EP4 agonist plays a greater role in osteo-
enic processes than bFGF.15 The EP4 agonist induced
allus formation and increased the volume of both cancel-
ous bone and osteoidas, as well as the number of osteo-
lasts. In the previous series, only the BMC was increased
y bFGF9; however, in the present study the EP4 agonist
ncreased both the BMC and BMD, thereby indicating the
uperiority of the EP4 agonist as an osteogenic agent when
ompared with bFGF.
SWCs could not be completely prevented with bFGF
lone9 or with the EP4 agonist alone; however, a combina-
ion of bFGF and the EP4 agonist might support each other.
lthough bFGF significantly recovered the peristernal
lood perfusion, it increased only the BMC in the ischemic
ternum of diabetic rats, whereas the EP4 agonist increased
oth the BMC and BMD without recovery of the peristernal
lood perfusion. Therefore a combination of the angiogenic
ffect of bFGF and the osteogenic effect of the EP4 agonist
ight provide more satisfactory results.
We used streptozotocin-induced diabetic rats in the
resent study. This diabetic model showed delayed wound
ealing, which might have been caused by a small vascular
hange and impaired leukocyte physiology caused by hy-
erglycemia. Hyperglycemia followed by vascular alter-
tions is the most common cause of morbidity and mortality
n diabetic patients. Several studies have reported on the
ndothelial dysfunction and functional alterations in the
icrocirculation of diabetic patients, such as increased vas-ular permeability, alterations in erythrocyte velocity, se- s
92 The Journal of Thoracic and Cardiovascular Surgery ● Marcuestration (entrapment) of leukocytes in the microcircula-
ion, and morphologic alterations, such as altered vascular
ensity.20 Leukocytes that are adherent to vascular endothe-
ium have been shown to cause capillary occlusion and
ndothelial cell apoptosis.21 In addition, hyperglycemia-
nduced neutrophil dysfunction is strongly correlated with
ncreased susceptibility to infection and delayed wound
ealing.22
Recent clinical studies have reported that harvesting of
he BITAs in a skeletonized fashion lowers the risk of
ternal infection, even in patients with diabetes.7,8 Harvest-
ng the ITA in a skeletonized fashion might preserve greater
ollateral blood flow than that in a pedicled fashion.23,24
owever, all collateral vessels cannot be preserved; this is
ue to anatomic and not technical reasons.25,26 Three types
f collateral vessels were identified to possess the potential
o supply blood to the sternum after the mobilization of the
nternal thoracic artery. The blood flow to the sternum was
reserved after the ligation of the collateral vessels, such as
he sternal-intercostal branch, whereas the ligation of the
ollateral vessels, such as the sternal-perforating branch, or
oncollateral vessels resulted in loss of the blood supply.25
herefore, even careful skeletonization destroys the collat-
rals from the lateral chest wall to the sternum. This trial
ith the EP4 agonist is a novel regenerative approach for
he devascularized sternum, irrespective of the harvesting
echniques used by surgeons.
We used fibrin glue as a scaffold for the PLGA micro-
pheres that were incorporated with the EP4 agonist. Fibrin
lue, a composite of fibrinogen and thrombin, is a suitable
iologic vehicle for cell transplantation because it has been
roved to be biocompatible and biodegradable and is capa-
le of binding to cells.27,28 It is also used as a slow and local
elivery vehicle for drugs such as losartan.28 PLGA, a
elivery vehicle for the EP4 agonist, itself is commonly
sed as a slow-release carrier for drugs. First, we dispersed
he microspheres containing the EP4 agonist in a surfactant
Tween 80) and injected it directly into the anterior medi-
stinal space; however, the osteogenic effect was weak (data
ot shown). This might be due to the rapid spread of the
icrospheres in the thoracic cavity. Then we applied the
brin glue as a scaffold for the PLGA microspheres and
btained satisfactory results. The fibrin glue itself did not
xhibit osteogenic effects in this devascularized sternum
odel of diabetic rats.
The present study has several limitations. First, the
odel used in this study has a narrow and thin sternum, and
ts anatomic features differ from those of human subjects.
he structural differences might influence sternal healing
nduced by the EP4 agonist. Additional investigations with
arge-animal models are required before studies on human
ubjects. Second, we did not examine the most suitable
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CDelease periods for sternal healing by changing the release
rofile.
In conclusion, the PGE2 EP4 receptor–selective agonist
ccelerated healing of the devascularized sternum and de-
reased the incidence of SWCs, even in diabetic rat models.
his method might potentially enable the wider application
f BITAs in coronary artery bypass surgery in high-risk
atients with diabetes and provides excellent long-term
esults. Furthermore, fast healing of the sternum shortens
he patients’ hospital stay, considerably decreases health
are costs, and facilitates the patients’ return to work or
ocial activities.
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